John Vandermosten outlines some gene therapy companies to watch - found funding in Q2
Precision Biosciences is a gene editing company that was able to raise $110 million in June. They are using what is called a homing endonuclease which can potentially recognize very specific DNA sequences and replace them with new DNA sequences.
Beam Therapeutics was another of the top capital getters with its gene editing platform focused on CRISPR-Cas9. They launched with earliest stage Series A funding of $87 million led by F-Prime Capital Partners and ARCH Venture Partners.
John Vandermosten is currently a senior biotechnology research analyst for Zacks Investment Research where he covers a portfolio of small cap biotechnology names.
Senior Biotechnology Analyst
Zacks Small Cap Research